<DOC>
	<DOC>NCT03052569</DOC>
	<brief_summary>Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.</brief_summary>
	<brief_title>Expanded Access to RXDX-105 for Cancers With RET Alterations</brief_title>
	<detailed_description />
	<criteria>Diagnosis of advanced cancer with RET alterations Unable to participate in an ongoing RXDX105 clinical trial Willing and able to provide written, signed informed consent Medically suitable for treatment with RXDX105 Prior treatment with a TKI that has activity against RET alterations Currently enrolled in an ongoing clinical study with any other investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>